Biotech news
Americas
Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen. 18 November 2020
Americas
The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report. 18 November 2020
Pharma
In response to the surge of COVID-19 infections worldwide, 18 generic drug makers have pledged to join the effort by the Medicines Patent Pool to accelerate global access to effective COVID-19 treatments via a pool for voluntary product licences. 17 November 2020
Americas
The US Food and Drug Administration will today announce that it plans to grant a Chinese-owned testing company an exclusive worldwide licence for a US government-owned patent covering a diagnostic test for the rapid detection of COVID-19. 13 November 2020
Pharma
The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19. 12 November 2020
Biotech
Australia has secured 40 million doses of a COVID-19 vaccine candidate in a deal with US biotechnology company Novavax. 5 November 2020
Biotech
Discretionary denials at the Patent Trial and Appeal Board, the CRISPR landscape and section 101 are top of mind for Eldora Ellison, director at Sterne Kessler Goldstein & Fox. 28 October 2020
Biotech
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report. 27 October 2020
Pharma
Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US. 22 October 2020
Biotech
Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement. 20 October 2020